Introduction
============

Stroke is the one of the most common diseases worldwide, with a high disability, mortality and recurrence rate, and usually leads to serious damage of central nervous system ([@B21]). There are three types of stroke, including ischemia stroke, cerebral hemorrhage, and cerebral thrombosis. Ischemia stroke, also been known as cerebral infarction, is the most commonly seen in stroke, with the highest morbidity about 70% ([@B36]). Although the main pathology clearly defined, namely that brain tissue hypoxic ischemia is caused by atherosclerosis of cerebral arteries, alone or with superimposed thrombosis, hypertension, diabetes mellitus, and cardiovascular disease ([@B75]; [@B13]), the corresponding precautionary measures are still limited in preventing the incidence rate.

Currently, the conventional therapy (CT), including thrombolysis, restoring blood supply to ischemic area, controlling cerebral edema, cerebral protection agents, preventing and treating complications, controlling hypertension, reducing blood viscosity, and so on, is the main clinical therapy for cerebral infarction ([@B7]). Recently, the theory that complementary medicine can substantial improve the disease has been put forward ([@B48]).

Xingnaojing injection (XNJ) is composed of musk, synthetic borneol, *Curcuma aromatica* Salisb, and *Gardenia jasminoides* J.Ellis derived from a classic traditional Chinese emergency prescription named An-Gong-Niu-Huang pill. It is widely used to treat nervous system disorders in China ([@B11]). Numerous studies indicating that the main active ingredients are muscone, borneol, camphor, curcumin, and curzerenone, and demonstrated borneol could be as a quality control substance, and it should be no less than 0.7 mg per ml XNJ injection. According to the above, the clinical widely used of XNJ are the quality assurance. In recent years, there was an increase of clinical and pharmacological research indicating that XNJ can ameliorate brain function and promote the recovery of consciousness. The mechanisms might include scavenging free radicals, improving cerebral edema and hypoxia, and increasing the metabolic rate and activity of brain cells ([@B16], [@B15]; [@B10]; [@B38]). However, there is no comprehensive and systematic evidence to confirm its clinical efficacy. Therefore, a comprehensive meta-analysis was performed in order to systematically evaluate the effectiveness of XNJ combined with CT for the treatment of cerebral infarction compared with the CT alone.

Materials and Methods {#s1}
=====================

The Literature Search Strategy
------------------------------

All RCTs concerning the effectiveness and safety of XNJ in treating cerebral infarction were retrieved from six databases, including PubMed, EMBASE, Cochrane Library, Wanfang database, VIP medicine information system, and China National Knowledge Infrastructure Database (CNKI) from inception to November 26, 2016, in terms of the keywords of "Xingnaojing injection" \[Title/Abstract\] AND "ischemia stroke" \[Title/Abstract\] OR "cerebral infarction" \[Title/Abstract\]. The searched results were downloaded for the further screening.

Inclusion and Excluded Criteria
-------------------------------

The literatures screening was performed by two investigators (Yuxue Yang and Tao Wang) independently. The title, abstract, and full-text were browsed in sequence to evaluate whether the study should be included according to the inclusion and exclusion criteria. The screening criteria were predesigned before screening, and the discussion was organized to evaluate the appropriateness of the studies if any divergences were observed.

### Inclusion Criteria

The inclusion criteria were as follows: (1) Randomized controlled trials (RCTs); (2) Patients who were suffering from cerebral infarction according specific diagnosis criteria; (3) There were no other medicines in combination with the CT in the experimental group, except for Xingnaojing injection, compared with the CT as a control; (4) Treatment duration had to be at least 14 days; (5) One or more outcome measures, including the overall response rate, neurological deficit score, serum level of matrix metalloproteinase (MMPs), hemorheology, blood lipid, hemodynamic, clinical symptom improvement (including activities of daily living, ADL; Glasgow Coma Scale, GCS; and infarction size) a must be included in each study.

### Exclusion Criteria

The study met with the following items would be excluded: (1) Duplicated articles, reviews, non-clinical studies, case observations; (2) Trials were not RCTs; (3) Combined with any other specific medicines in control group or experimental during the treatment.

Data Extraction and Risk of Bias Assessment
-------------------------------------------

Two investigators (Yuxue Yang and Tao Wang) independently performed the data extraction and quality assessment of the included studies. The baseline information, including first author, publication year, the cases of experimental and control groups, respectively, interventions of experimental group, outcome measures were extracted to yield a conclusion table.

All the included RCTs were assessed for methodological quality using the Cochrane Handbook for Systematic Reviews of Interventions ([@B17]). Five items, including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting were used for the methodological quality of each included studies. The quality of each item was assessed using the three levels of "low risk," "high risk," or "unclear risk."

Data Analysis
-------------

Cochrane Review Manager 5.3 (Cochrane Collaboration) was used for statistical analysis. Dichotomous variables, such as overall response rate, were presented as odds ratio (*OR*), while the continuous variables, including the neurological deficit score, serum level of matrix metalloproteinase (MMPs), hemorheology, blood lipid, hemodynamic were presented as mean difference (*MD*) with 95% confidence intervals (95% CI). Additionally, the statistical heterogeneity was estimated using *P*-value and *I*-square (*I*^2^) statistic tests. Data with *P* ≥ 0.10 and *I*^2^ ≤ 50% were defined as low heterogeneity, and a fixed-effects model would be used for the meta-analysis, whereas, a random-effects model was used for data with substantial heterogeneity (*P* \< 0.10, *I*^2^\> 50%). The publication bias was estimated by a funnel plot.

Results
=======

Search Results
--------------

Nine hundred and eight publications were retrieved according to the search strategy. After the title and abstract browsing, 507 articles were removed for duplicated. 348 reviews were excluded for the following reasons: non-randomized controlled studies, animal studies, ambiguous outcome measures and overlapping data with another study, and combination with other medicines. Ultimately, 53 eligible articles with 4915 participants (2475 cases in the experimental group, 2440 cases in the control group) were included in the meta-analysis according to the inclusion and exclusion criteria after the full-text reading (**Figure [1](#F1){ref-type="fig"}**).

![Flow diagram of the literature screening.](fphar-08-00485-g001){#F1}

Study Characteristics and Methodological Quality of Included Trials
-------------------------------------------------------------------

Among the 53 included trails, which were published between 1999 and 2016, all were RCTs with a comparison between a combination of XNJ and CT with CT treatment alone. The dosage of administered XNJ ranged from 10 to 40 mL/day via intravenous drip. There was no significant difference between the experimental and control groups in general information (**Table [1](#T1){ref-type="table"}**).

###### 

Characteristics and outcome measures of included studies.

  Included research (year)   E/C       Intervening measure (E/C)   Dosage of XNJ   Duration      Outcome measures
  -------------------------- --------- --------------------------- --------------- ------------- ----------------------------------------------------------------------
  [@B63]                     20/20     XNJ+ CT vs. CT              40 mL/day       15 days       Overall response rate
  [@B5]                      39/30     XNJ+ CT vs. CT              20 mL/day       20 days       Overall response rate, Hemorheology, Blood lipid
  [@B71]                     32/28     XNJ+ CT vs. CT              30 mL/day       15 days       Neurological deficit score
  [@B26]                     27/27     XNJ+ CT vs. CT              20 mL/day       2 weeks       GCS
  [@B45]                     39/30     XNJ+ CT vs. CT              20 mL/day       20 days       Overall response rate
  [@B61]                     40/40     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate
  [@B4]                      73/84     XNJ+ CT vs. CT              30 mL/day       2 weeks       Neurological deficit score
  [@B31]                     76/64     XNJ+ CT vs. CT              40 mL/day       15 days       Neurological deficit score
  [@B42]                     30/30     XNJ+ CT vs. CT              20 mL/day       3 weeks       Hemorheology, Overall response rate, Blood lipid
  [@B62]                     54/52     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate, neurological deficit score
  [@B20]                     30/28     XNJ+ CT vs. CT              20 mL/day       15 days       Overall response rate
  [@B27]                     50/50     XNJ+ CT vs. CT              30 mL/day       2 weeks       Overall response rate, neurological deficit score
  [@B6]                      30/30     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate, neurological deficit score
  [@B12]                     43/43     XNJ+ CT vs. CT              20 mL/day       20--28 days   Neurological deficit score, Overall response rate
  [@B24]                     30/30     XNJ+ CT vs. CT              20 mL/day       2 weeks       Neurological deficit score, Overall response rate
  [@B41]                     40/40     XNJ+ CT vs. CT              20--30 mL/day   2 weeks       Overall response rate, neurological deficit score
  [@B50]                     70/66     XNJ+ CT vs. CT              30 mL/day       2 weeks       Overall response rate, neurological deficit score
  [@B53]                     30/30     XNJ+ CT vs. CT              20 mL/day       3 weeks       Hemorheology, Blood lipid, neurological deficit score
  [@B53]                     40/40     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate, neurological deficit score
  [@B65]                     62/62     XNJ+ CT vs. CT              20 mL/day       15 days       Overall response rate
  [@B69]                     49/49     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate
  [@B25]                     43/43     XNJ+ CT vs. CT              20 mL/day       2 weeks       Neurological deficit score, Overall response rate
  [@B25]                     30/31     XNJ+ CT vs. CT              20 mL/day       2 weeks       Neurological deficit score, Overall response rate, Blood lipid
  [@B51]                     64/66     XNJ+ CT vs. CT              30 mL/day       2 weeks       Overall response rate, neurological deficit score
  [@B55]                     100/100   XNJ+ CT vs. CT              20 mL/day       30 days       NIHSS, Overall response rate
  [@B8]                      35/33     XNJ+ CT vs. CT              20 mL/day       2 weeks       Neurological deficit score
  [@B30]                     75/75     XNJ+ CT vs. CT              40 mL/day       2 weeks       Overall response rate, neurological deficit score
  [@B40]                     40/40     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate, neurological deficit score
  [@B70]                     49/49     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate
  [@B19]                     96/96     XNJ+ CT vs. CT              20 mL/day       2 weeks       Infarction size, neurological deficit score
  [@B34]                     60/60     XNJ+ CT vs. CT              20 mL/day       2 weeks       Neurological deficit score, Overall response rate, ADL, Hemorheology
  [@B37]                     62/62     XNJ+ CT vs. CT              20 mL/day       15 days       Overall response rate, MMPs
  [@B44]                     45/41     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate, GCS
  [@B46]                     38/38     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate, MMPs
  [@B52]                     30/30     XNJ+ CT vs. CT              20--30 mL/day   2 weeks       Overall response rate, neurological deficit score
  [@B59]                     50/50     XNJ+ CT vs. CT              40 mL/day       1 week        NHISS
  [@B68]                     52/52     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate, MMP-9
  [@B67]                     20/20     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate, NHISS
  [@B73]                     49/49     XNJ+ CT vs. CT              10 mL/day       30 days       Neurological deficit score
  [@B1]                      64/64     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate, Infarction size, neurological deficit score
  [@B28]                     24/23     XNJ+ CT vs. CT              20 mL/day       NR            Overall response rate
  [@B35]                     50/50     XNJ+ CT vs. CT              10--20 mL/day   4 weeks       Overall response rate, Hemodynamics
  [@B47]                     42/42     XNJ+ CT vs. CT              20 mL/day       NR            MMP-9, Overall response rate
  [@B54]                     60/60     XNJ+ CT vs. CT              10--20 mL/day   20 days       Neurological deficit score, ADR
  [@B74]                     35/35     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate, neurological deficit score
  [@B3]                      58/58     XNJ+ CT vs. CT              20 mL/d         2 weeks       MMPs, Overall response rate
  [@B29]                     30/30     XNJ+ CT vs. CT              20 mL/day       10 days       Neurological deficit score
  [@B32]                     35/35     XNJ+ CT vs. CT              30 mL/day       2 weeks       Overall response rate, neurological deficit score, Infarction size
  [@B32]                     35/35     XNJ+ CT vs. CT              30 mL/day       2 weeks       ADL
  [@B56]                     72/72     XNJ+ CT vs. CT              20 mL/day       30 days       Hemodynamics, Overall response rate
  [@B56]                     40/40     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate
  [@B64]                     48/48     XNJ+ CT vs. CT              20 mL/day       2 weeks       Overall response rate
  [@B66]                     40/40     XNJ+ CT vs. CT              20 mL/day       15 days       Overall response rate

E, experimental group; C, control group; NR, no report

.

The methodological quality of included studies was estimated according to the Cochrane risk of bias estimation. All of the included trails mentioned randomized allocation, whereas, only 5 of them mentioned the appropriate generation of the random allocation sequence ([@B41]; [@B8]; [@B28]; [@B33]; [@B32]). There was no trails mentioned allocation concealment. Three of the 53 studies stated double blind design (blinding of participants and blinding of outcome assessment) ([@B26]; [@B4]; [@B37]). Two of 53 studies were published with a high risk of incomplete outcome ([@B12]; [@B57]), and the risk of selective reporting was high for the three trials ([@B27]; [@B6]; [@B55]) (**Figure [2](#F2){ref-type="fig"}**).

![Methodological quality assessment of the risk of bias for each included study.](fphar-08-00485-g002){#F2}

Analysis and Subgroup Analysis for Outcome Measures
---------------------------------------------------

### The Overall Response Rate

Thirty-eight of the 53 trials ([@B63]; [@B5], [@B6]; [@B45]; [@B61]; [@B42]; [@B27]; [@B12]; [@B24]; [@B41]; [@B50]; [@B53], [@B55]; [@B65], [@B66]; [@B69]; [@B22]; [@B25]; [@B51]; [@B30]; [@B40]; [@B70]; [@B34]; [@B37]; [@B44]; [@B46]; [@B52]; [@B67]; [@B68]; [@B1]; [@B35]; [@B47]; [@B74]; [@B3]; [@B32]; [@B57]; [@B56]; [@B64]) compared the overall response rate between XNJ combined with CT treatment and single CT treatment. There was no heterogeneity (*P* = 1.0, *I*^2^ = 0%), and a fixed-effect model was used to carry out the meta-analysis. An *OR* with 95% CI was used to present the comparison of overall response rate between the experimental and control groups (*OR* = 3.56, 95% CI \[2.94, 4.32\], *P* \< 0.00001). It revealed that XNJ could significantly increase the treatment efficacy of CT for cerebral infarction (**Figure [3](#F3){ref-type="fig"}**).

![Forest plot of overall response rate comparing the experimental and control groups. *I*^2^ and *P* are the criterion for the heterogeneity test, ![](fphar-08-00485-i001.jpg) pooled odds ratio, ![](fphar-08-00485-i002.jpg) odds ratio and 95% CI.](fphar-08-00485-g003){#F3}

### The Neurological Deficit Score

Thirty trials with 3518 participants measured the neurological deficit score, and there were two evaluation criterions, including the National Institutes of Health Stroke Scale (NIHSS) ([@B4]; [@B62]; [@B6]; [@B58]; [@B53], [@B55]; [@B19]; [@B59]; [@B68]; [@B1]; [@B32]; [@B56]), and the Chinese Stroke Scale (CSS, the fourth national cerebral vascular disease in 1995) ([@B71]; [@B27]; [@B12]; [@B24]; [@B41]; [@B50]; [@B25]; [@B22]; [@B51]; [@B8]; [@B30]; [@B40]; [@B34]; [@B52]; [@B73]; [@B54]; [@B74]; [@B29]) used. As shown in **Figure [4](#F4){ref-type="fig"}**, there were substantial heterogeneity both in the two subgroups (*P* \< 0.00001, *I*^2^ = 92%; *P* \< 0.00001, *I*^2^ = 87%). A random effects model was used to pool this meta-analysis. The result of this meta-analysis showed that the neurological deficit score of patients in the experimental group was much lower, compared with the control group according to both of the two evaluation criterions (*MD* = -3.44, 95% CI \[-4.52, -2.36\], *P* \< 0.00001; *MD* = -5.72, 95% CI \[-6.94, -4.50\], *P* \< 0.00001).

![Forest plot of neurological deficit score comparing the experimental and control groups. *I*^2^ and *P* are the criterion for the heterogeneity test, ![](fphar-08-00485-i001.jpg) pooled odds ratio, ![](fphar-08-00485-i002.jpg) odds ratio and 95% CI.](fphar-08-00485-g004){#F4}

### Serum Levels of MMPs

The serum levels of MMP-2 and MMP-9 were measured. There were two studies ([@B46]; [@B3]) involving 192 patients measured the level of MMP-2, and 5 studies with 504 participants measured the level of MMP-9. The random-effects model was used to pool this meta-analysis for the significant heterogeneity of them (*P* = 0.04, *I*^2^ = 76%; *P* = 0.02, *I*^2^ = 66%). The pooled analysis showed that compared with the CT, the XNJ could significantly reduce the serum levels of MMP-2, and MMP-9 (*MD* = -11.24, 95% CI \[-20.83, -1.65\], *P* = 0.02; *MD* = -25.08, 95% CI \[-35.49, -14.67\], *P* \< 0.00001) (**Figure [5](#F5){ref-type="fig"}**).

![Forest plot of serum levels of MMPs comparing the experimental and control groups. **(A)** Forest plot of serum level of MMP-2; **(B)** forest plot of serum level of MMP-9. *I*^2^ and *P* are the criterion for the heterogeneity test, ![](fphar-08-00485-i001.jpg) pooled odds ratio, ![](fphar-08-00485-i002.jpg) odds ratio and 95% CI.](fphar-08-00485-g005){#F5}

### Hemorrheology Improvement

The hemorrheology, including whole blood viscosity (WBV), plasma viscosity (PV), and hematocrit (HCT) was measured in five studies ([@B5]; [@B42]; [@B58]; [@B34]; [@B44]). The random-effects model was used for the substantial heterogeneity of the three subgroups (*P* \< 0.00001, *I*^2^ = 87%; *P* = 0.006, *I*^2^ = 73%; *P* \< 0.00001, *I*^2^ = 96%). As shown in **Figure [6](#F6){ref-type="fig"}**, XNJ was more effective in improving hemorrheology by reducing WBV, PV, and HCT comparing with CT (*MD* = -1.44, 95% CI \[-2.18, 0.70\], *P* = 0.001; *MD* = -0.22, 95% CI \[-0.37, -0.07\], *P* = 0.003; *MD* = -3.63, 95% CI \[-6.23, -1.03\], *P* = 0.006).

![Forest plot of hemorrheology improvement comparing the experimental and control groups. **(A)** Forest plot of whole blood viscosity; **(B)** forest plot of plasma viscosity. **(C)** Forest plot of hematocrit. *I*^2^ and *P* are the criterion for the heterogeneity test, ![](fphar-08-00485-i001.jpg) pooled odds ratio, ![](fphar-08-00485-i002.jpg) odds ratio and 95% CI.](fphar-08-00485-g006){#F6}

### Hemodynamics Improvement

There were two studies ([@B35]; [@B57]) reporting the hemodynamics (peak-flow rate, and average velocity) improvement. Heterogeneity between the two studies was significant (*P* = 0.06, *I*^2^ = 71%; *P* = 0.02, *I*^2^ = 81%). Hence, a random-effects model was used to pool the meta-analysis. The results revealed that compared with the CT, XNJ could remarkably increase the peak-flow rate, and average velocity (*MD* = 12.66, 95% CI \[10.50, 14.81\], *P* \< 0.00001; *MD* = 9.90, 95% CI \[8.63, 11.17\], *P* \< 0.00001) (**Figure [7](#F7){ref-type="fig"}**).

![Forest plot of hemodynamics improvement comparing the experimental and control groups. **(A)** Forest plot of peak-flow rate; **(B)** forest plot of average velocity. *I*^2^ and *P* are the criterion for the heterogeneity test, ![](fphar-08-00485-i001.jpg) pooled odds ratio, ![](fphar-08-00485-i002.jpg) odds ratio and 95% CI.](fphar-08-00485-g007){#F7}

### Blood Lipid Amelioration

There were four studies ([@B5]; [@B42]; [@B58]; [@B22]) reported the amelioration of blood lipid after the treatment of XNJ and CT, respectively. There was no significant heterogeneity among the individual trails (*P* = 0.92, *I*^2^ = 0%; *P* = 0.93, *I*^2^ = 0%). The meta-analysis, using the fixed-effects model, revealed that compared with the CT, XNJ could significantly reduce the levels of cholesterol and triglyceride in blood (*MD* = -1.06, 95% CI \[-1.21, -0.92\], *P* \< 0.00001; *MD* = -1.05, 95% CI \[-1.12, -0.97\], *P* \< 0.00001) (**Figure [8](#F8){ref-type="fig"}**).

![Forest plot of blood lipid amelioration comparing the experimental and control groups. **(A)** Forest plot of cholesterol; **(B)** forest plot of triglyceride. *I*^2^ and *P* are the criterion for the heterogeneity test, ![](fphar-08-00485-i001.jpg) pooled odds ratio, ![](fphar-08-00485-i002.jpg) odds ratio and 95% CI.](fphar-08-00485-g008){#F8}

### Clinical Symptoms Improvement

The clinical symptoms, including ADL, GCS, and infarct size were measured. There were five trails ([@B63]; [@B58]; [@B34]; [@B32]; [@B33]) reported the ADL improvement. As shown in **Figure [9A](#F9){ref-type="fig"}**, XNJ could significantly improve the ADL of patients with cerebral infarction, compared with the CT (*MD* = 10.23, 95% CI \[9.47, 10.99\], *P* \< 0.00001). There was no significant heterogeneity among the individual studies (*P* = 0.67, *I*^2^ = 0%), and a fixed-effects model was used to pool this meta-analysis. As for coma scale improvement, there was no significant difference between the experimental and control groups (*MD* = 1.00, 95% CI \[-0.96, 2.96\], *P* = 0.32) (**Figure [9B](#F9){ref-type="fig"}**). Additionally, XNJ could significantly decrease the infarct size (*MD* = -1.83, 95% CI \[-2.49, -1.16\], *P* \< 0.00001). Heterogeneity between the studies was substantial, and a random-effects model was used (*P* = 0.03, *I*^2^ = 78%) (**Figure [9C](#F9){ref-type="fig"}**).

![Forest plot of clinical symptom improvement comparing the experimental and control groups. **(A)** Forest plot of activities of daily living; **(B)** forest plot of Glasgow Coma Scale; **(C)** forest plot of infarct size. *I*^2^ and *P* are the criterion for the heterogeneity test, ![](fphar-08-00485-i001.jpg) pooled odds ratio, ![](fphar-08-00485-i002.jpg) odds ratio and 95% CI.](fphar-08-00485-g009){#F9}

### Publication Bias

A funnel plot was used to evaluate the publication bias. A total of 38 trails included in the funnel plot of the overall response rate. As shown in **Figure [10](#F10){ref-type="fig"}**, there was no significant asymmetry observed.

![Funnel plot for the publication bias of the overall response rate.](fphar-08-00485-g010){#F10}

Discussion
==========

Cerebral infarction, known as ischemia stroke, is one of the common cerebrovascular diseases with high morbidity and mortality and seriously endangering the health and daily life of patients ([@B2]). It has been widely recognized one of the primary causes of death and disability both in developed and developing countries ([@B2]). CT, including thrombolysis, improving microcirculation, the applying of neuroprotective agents restoring, blood supply to ischemic area, controlling cerebral edema, preventing and treating complications, controlling hypertension, reducing blood viscosity, etc. is the main clinical therapy for the patients with cerebral infarction in current years. However, the motor weakness on one or both sides of body may be caused by the frequently used of conventional agents ([@B23]). Therefore, the more effective agents for cerebral infarction patients are desirable.

Traditional Chinese medicine has been used to treat stroke in China during the past 2,000 years. Advanced pharmaceutical technologies have led to the development of many oral agents and injections for the prevention and treatment of stroke that are based on well-known traditional Chinese medical prescriptions ([@B60]). It has been demonstrated that XNJ to be an effective agent for reducing brain injuries, and enhancing functional recovery. However, a comprehensive and systematic evaluation of XNJ for the treatment of cerebral infarction is rare, according to current rigorous international standards ([@B14]). The aim of this review was to provide an internationally accessible systematic review of the clinical efficacy and safety of XNJ for the cerebral infarction.

A recent meta-analysis indicated that XNJ could significantly increase efficacy rate, decrease neurological deficit scores and the serum level of TNF-α of the patients of stroke. The statistical analysis found that the primary mechanism of XNJ activity was neuroprotective effect via improvement of cerebral circulation and blood flow and a reduction of cerebral edema, ferritin, and inflammation ([@B39]). In this review, we further explored the effect of XNJ on cerebral infarction and provided extended findings. First of all, overall response rate and neurological deficit score were chosen to measure the clinical efficacy of XNJ according to the "the criteria for the degree of defect of the clinical function of the patients in stroke" in the fourth academic conference on cerebrovascular disease ([@B49]), which were direct correlated to improvement of patients with cerebral infarction. Compared with CT alone, XNJ combined with CT was associated with relatively higher overall response rate and lower neurological deficit score (*P* \< 0.00001, *P* \< 0.00001, respectively). The combination therapy also alleviated the clinical symptom of patients with cerebral infarction, including improving ADL, reducing infarction size (*P* \< 0.00001, *P* \< 0.00001, respectively). It did not result in a statistically significant improvement of the GCS (*P* = 0.32). The result of GCS improvement was based on two small-samples. Therefore, additional trails are necessary for a better data basis.

Meanwhile, the mechanism of XNJ activity for cerebral infarction was explored. The accumulating data revealed that MMPs are deleterious in stroke, in particular MMP-2 and MMP-9 ([@B43]; [@B9]). The result of our meta-analysis suggested that based on the CT, XNJ could significantly lower the level of MMP-2 and MMP-9 (*P* = 0.02, *P* \< 0.00001). Additionally, the hermorrheology (including WBV, PV, and HCT) and hemodynamics (Vp, and Vm) were measured to evaluate the treatment effect of XNJ on cerebral infarction. As shown in **Figure [6](#F6){ref-type="fig"}**, XNJ could significantly improve the hemorrheology by reducing WBV, PV, and HCT (*P* = 0.0001, *P* = 0.003, *P* = 0.006, respectively) based on the CT. And at the same time, the hemodynamics was also significantly improved (*P* \< 0.00001, *P* \< 0.00001). There were significant correlation between occurrence of ischemic stroke and dyslipidemia. When the total cholesterol (Chol) increased by 1 mmol/L, the incidence of stroke will increase by 25% ([@B72]; [@B18]). In the systematic review, four trails mentioned the blood lipid change, including Chol and TG. The meta-analysis demonstrated that there were significant differences between the experimental and control groups in Chol and TG (*MD* = -1.06, 95% CI \[-1.21, -0.92\], *P* \< 0.00001; *MD* = -1.05, 95% CI \[-1.12, -0.97\], *P* \< 0.00001). Accordingly, blood lipids level may be proposed as one of the important indicators for the evaluation of efficacy of XNJ for treating cerebral infarction in the further clinical studies.

The efficacy and adverse events associated with XNJ in treatment of cerebral infarction were explored via extensive researches and strict methodologies. However, there are limitations to this research, such as the quality of the included data for the original trials. Many RCTs do not employ strict methodologies. Additionally, most of the involving patients were Chinese. It is necessary to including more varied population sample. The sample size, selection criteria varied for the included studies. We were unable to perform a subgroup analysis.

Conclusion
==========

These findings reflect that XNJ may significantly improve overall response rate, neural functional, Hemodynamics and ADL, and decrease the blood viscosity, serum levels of MMPs, the level of blood lipid and infarction size. It is likely that XNJ also decreases the Glasgow Coma Scale, but the results were not statistically significant. However, our findings must be interpreted with caution because of the small sample size and limitations of the study. Several rigorous, large-scale RCTs are necessary to confirm these results.
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